basimglurant
Small moleculeexperimental
Basimglurant is a negative allosteric modulator of the mGlu5 receptor which is under development by Roche and Chugai Pharmaceutical for the treatment of treatment-resistant depression and fragile X syndrome. As of November 2016, it has undergone phase II clinical trials for both of these indications. — Wikipedia
Clinical trial activity
15 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
6
Phase 3
1
Phase 4
0
Earliest trial started Mar 1, 2009 (NCT00809562)
Timeline
Indications
Mechanism of action
- Metabotropic glutamate receptor 5MODULATOR
GRM5 modulator
Negative allosteric modulator (NAM)
Chemistry & pharmacology
Loading structure…
SMILES
Cc1nc(C#Cc2ccnc(Cl)c2)c(C)n1-c1ccc(F)cc1- Mol. weight
- 325.77 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaBasimglurant ↗
- ChEMBLCHEMBL3301626 ↗
Also known as
- 2-chloro-4-(1-(4-fluorophenyl)-2,5-dimethyl-1h-imidazol-4-ylethynyl)pyridine
- basimglurant
- basimglurant
- basimglurant
- basimglurant
- basimglurant
- rg-7090
- rg-7090
- ro4917523
- ro4917523
- ro4917523
- ro-4917523
- ro-4917523
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05217628 | Phase 2/Phase 3 (Phase 3) | Jan 11, 2022 | Noema Pharma AG |
| NCT05059327 | Phase 2 | Nov 22, 2021 | Noema Pharma AG |
| NCT02433093 | Phase 1 | Apr 1, 2015 | Roche |
| NCT01873508 | Phase 1 | Jun 1, 2013 | Roche |
| NCT01750957 | Phase 2 | Feb 1, 2013 | Roche |
| NCT01665404 | Phase 1 | Jul 1, 2012 | Roche |
| NCT01629368 | Phase 1 | Jun 1, 2012 | Roche |
| NCT01517698 | Phase 2 | May 1, 2012 | Roche |
| NCT01592890 | Phase 1 | Apr 1, 2012 | Roche |
| NCT01483469 | Phase 1 | Dec 1, 2011 | Roche |
| NCT01437657 | Phase 2 | Oct 1, 2011 | Roche |
| NCT01368926 | Phase 1 | Jun 1, 2011 | Roche |
| NCT01045083 | Phase 1 | Jan 1, 2010 | Roche |
| NCT01015430 | Phase 2 | Nov 1, 2009 | Roche |
| NCT00809562 | Phase 2 | Mar 1, 2009 | Roche |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 13 | 13 | 2 | 2009 |
| Noema Pharma AG | For profit | 2 | 2 | 2 | 2021 |
2 organizations
Page 1 / 1